Veraxa Biotech (NASDAQ:VRXA) Stock Price Crosses Above 50 Day Moving Average – Time to Sell?

Veraxa Biotech Holding AG (NASDAQ:VRXA)’s stock price crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $1.24 and traded as high as $1.3298. Veraxa Biotech shares last traded at $1.26, with a volume of 270,102 shares traded.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a report on Monday, August 31st.

Veraxa Biotech Stock Up 17.8%

The firm has a fifty day moving average of $1.24.

Insiders Place Their Bets

In other news, Director Christoph Samuel Ziegler purchased 30,000 shares of the business’s stock in a transaction dated Tuesday, October 20th. The stock was acquired at an average price of $1.09 per share, with a total value of $32,700.00. Following the purchase, the director directly owned 37,932 shares of the company’s stock, valued at $41,345.88. This represents a 378.21% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Oliver Baumann purchased 50,000 shares of the business’s stock in a transaction dated Thursday, August 27th. The shares were purchased at an average cost of $1.50 per share, with a total value of $75,000.00. Following the purchase, the director directly owned 5,773,618 shares in the company, valued at approximately $8,660,427. The trade was a 0.87% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have acquired 95,000 shares of company stock worth $125,333.

Veraxa Biotech Company Profile

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.